Ortho, Sphingotec ink strategic agreement on novel biomarker for decreasing re-hospitalizations in heart failureRead Now
Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, and sphingotec GmbH has announced a long-term, global strategic agreement regarding the endothelial function marker, biologically active Adrenomedullin (sphingotest bio-ADM), which measures patients’ rate of recovery from acute heart failure, providing critical information to physicians making treatment decisions. The agreement allows Ortho to use the sphingotest bio-ADM immunoassay on Ortho’s automated VITROS Immunodiagnostics and Integrated Systems for small-, mid- and high-volume clinical laboratories. Product availability is subject to local regulatory requirements.
“Ortho is committed to the continued expansion of our menu offerings, through both internal research and development programs and strategic collaborations,” said Robert Yates, Ortho’s chief operating officer. “Our strategic agreement regarding the sphingotest bio-ADM assay positions us to bring this novel cardiac biomarker to a broad range of clinical labs around the world.”
Congestion in acute heart failure, which is mainly caused by endothelial dysfunction, is a serious medical problem and a main driver of re-hospitalizations in these patients. Next to the wide use of natriuretic peptides mainly for the diagnosis of heart failure, accurate determination of residual congestion during and after treatment is a high unmet medical need, to assess the adequacy of acute heart failure therapy. In particular, residual heart congestion at hospital discharge is associated with a high risk of re-hospitalization and mortality, emphasizing the need for assessing and monitoring the adequacy of decongestion therapy throughout hospitalization. bio-ADM has been investigated in numerous clinical studies, showing its suitability to accurately diagnose residual congestion, monitor treatment effectiveness and determine suitability of patients for hospital discharge.
"Working with Ortho Clinical Diagnostics will help us deliver our standardized sphingotest bio-ADM assay to laboratories around the world to help them efficiently diagnose heart failure patients with residual congestion, in time for meaningful intervention, including a potential change in medication, to take place,” said Andreas Bergmann, founder and general manager of sphingotec GmbH.